Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Work In Process (2016 - 2020)

Historic Work In Process for United Therapeutics (UTHR) over the last 11 years, with Q1 2020 value amounting to $28.1 million.

  • United Therapeutics' Work In Process rose 684.41% to $28.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $28.1 million, marking a year-over-year increase of 684.41%. This contributed to the annual value of $29.1 million for FY2019, which is 392.86% up from last year.
  • United Therapeutics' Work In Process amounted to $28.1 million in Q1 2020, which was up 684.41% from $29.1 million recorded in Q4 2019.
  • United Therapeutics' Work In Process' 5-year high stood at $29.8 million during Q3 2019, with a 5-year trough of $22.9 million in Q1 2017.
  • For the 5-year period, United Therapeutics' Work In Process averaged around $26.2 million, with its median value being $26.2 million (2016).
  • Per our database at Business Quant, United Therapeutics' Work In Process skyrocketed by 2128.84% in 2016 and then tumbled by 1333.33% in 2017.
  • Quarter analysis of 5 years shows United Therapeutics' Work In Process stood at $24.9 million in 2016, then fell by 3.21% to $24.1 million in 2017, then rose by 16.18% to $28.0 million in 2018, then grew by 3.93% to $29.1 million in 2019, then dropped by 3.44% to $28.1 million in 2020.
  • Its Work In Process stands at $28.1 million for Q1 2020, versus $29.1 million for Q4 2019 and $29.8 million for Q3 2019.